Summary
- The Nasdaq-listed company, "Rikst Biotechnology," has announced its approval of a virtual asset accumulation strategy.
- The board of directors decided to invest up to 25% of the company's reserves in virtual assets.
- The CEO views virtual assets as a hedge against existing reserve assets and a means to create shareholder value, expressing trust in their long-term potential.
Rikst Biotechnology Holdings, a biopharmaceutical company listed on Nasdaq, plans to begin accumulating virtual assets (cryptocurrencies).
According to GlobeNewswire on the 13th (local time), Rikst Biotechnology announced in a press release, "The board of directors has approved a virtual asset accumulation strategy," and stated, "We will invest up to 25% of our corporate reserves in virtual assets."
Geordan Pursglove (CEO) said, "Virtual assets are a hedge against traditional reserve assets and a means to generate value for shareholders," adding, "We believe in the long-term potential of virtual assets."
Son Min
sonmin@bloomingbit.ioHello I’m Son Min, a journalist at BloomingBit
![[Analysis] "XRP risks repeating the 2022 rout…most short-term investors in the red"](https://media.bloomingbit.io/PROD/news/845f37bb-29b4-4bc5-9e10-8cafe305a92f.webp?w=250)
![[Exclusive] “Airdrops also taxable”... Authorities to adopt a ‘comprehensive approach’ to virtual assets](https://media.bloomingbit.io/PROD/news/4bde9dab-09bd-4214-a61e-f6dbf5aacdfb.webp?w=250)